Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma
Recombinant human erythropoietin (rHu-EPO) is an effective growth factor for erythroid progenitor cells in anemia provoked by several conditions, including bone marrow tumors such as multiple myeloma (MM). We studied a group of 54 patients with MM undergoing second-induction chemotherapy. Thirty of them were randomly assigned to receive rHu-EPO at an initial dosage of 150 units/kg body weight three times a week, increased to 300 units/kg from the sixth week to the end of the 24-week study. Hemoglobin (Hb) levels increased in 77.7% of these patients by the eighth week. In addition, five transfusion-dependent patients in treatment with the VMCP protocol completed the trial without requiring blood supplement after the third month, whereas seven control patients required frequent supplements. Monthly assessment of hematologic parameters demonstrated the ability of rHu-EPO to increase reticulocyte counts, whereas five patients became resistant to the second-induction chemotherapy in apparent concurrence with their rHu-EPO therapy. The response to rHu-EPO in four of the five MM patients receiving cytotoxic protocols combined with α-interferon (α-IFN) included an increase of serum IgM after the third month. This effect was not demonstrable in any other group, including three rHu-EPO-untreated patients undergoing α-IFN + VMCP combined therapy, as well as rHu-EPO-treated patients not receiving a-IFN. Our data suggest that α-IFN plus rHu-EPO treatment in MM patients is effective in restoring normal B cell function. These results may reflect in vivo the modulation of normal human B cells and lymphoblasts by rHu-EPO observed in vitro.
Key wordsAnemia α-Interferon Chemotherapy Multiple myeloma rHu-EPO
Unable to display preview. Download preview PDF.
- 6.Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 300:573–578Google Scholar
- 11.Depaoli L, Levis A, Isabella N, Ficara F, Priotto C, Lista P, Foà R, Resegotti L (1993) Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Haematologica (Pavia) 78:118–122Google Scholar
- 16.Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Ettenger RB (1990) Effects of recombinant human erythropoietin in HLA sensitization and cell-mediated immunity. Kidney Intern 38:12–19Google Scholar
- 17.Hellström E, Birgegärd G, Locker D, Helmers C, Öst Å, Wide L (1991) Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Hematol 47:355–366Google Scholar
- 20.Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Symposium held at the New York Academy of Medicine, New York (1948). Columbia University Press, New York, pp 191–205Google Scholar
- 21.Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H (1990) Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serumfree medium. Clin Exp Immunol 85:151–156Google Scholar
- 23.Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger T, Barnas V (1991) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699Google Scholar
- 24.McLauchein P, Alexanian R (1992) Myeloma protein kinetics following chemotherapy. Blood 60:851–855Google Scholar
- 33.Selbach J, Purea H, Westerhausen M (1989) Interferon alpha 2 B with chemotherapy in advanced or refractory multiple myeloma. Blut 59: S3, 326Google Scholar
- 36.Wahlin A, Holm J (1989) Rapid response to recombinant interferon alpha and high-dose prednisone in multiple drug-resistant multiple myeloma. Eur J Haematol 42:352–354Google Scholar